[New data in staging and prognosis of bronchopulmonary carcinoma. Part II: volumetric analysis of pulmonary nodules].

Pulmonary nodules discovered incidentally or in the context of the work-up for symptomatic conditions represent an area of major interest. By definition, a pulmonary nodule is defined as a well-circumscribed round or oval lesion, measuring less than 3 cm in maximal diameter. The impact of newer technologies on our capacity to detect pulmonary nodules has increased significantly in the last decade, from the utilization of high-performance computed tomographic (CT) scanners, to the development of more functional imaging techniques, such positron emission tomography (PET) scanners.

[New developments in staging and prognosis of bronchopulmonary carcinoma. Part I: Epidemiology and diagnostic investigations].

Lung cancer represents a major health problem globally and its surge in incidence is mainly attributed to the increase in the consumption of tobacco-related products. The poor prognosis of this condition is generally related to the advanced stage at the time of the diagnosis; therefore, accurate staging initially as well during the course of the disease seems to be of paramount importance. Unfortunately, in the last half-century, no major breakthroughs occurred in the field of the lung cancer therapy.

Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.

Purpose: The combination of Gemcitabine (GEM)/carboplatin (CBDCA) has demonstrated activity in the treatment of stage III and IV non-small-cell lung cancer (NSCLC). This phase III randomized trial compared the response rate, survival rate, and toxicity of the combination of GEM plus CBDCA with the combination of VLB plus CDDP.

Methods: Chemonaïve patients with advanced or metastatic NSCLC were enrolled in the study.